[1] NAKAGAWA T, UYAMA R, OHASHI E, et al. The expression of sialyl Lewis X in canine and feline mammary gland tumors[J]. J Vet Med Sci, 2002, 64(10):949-952.
[2] NATH S, MUKHERJEE P. MUC1:A multifaceted oncoprotein with a key role in cancer progression[J]. Trends Mol Med, 2014, 20(6):332-342.
[3] HOLLINGSWORTH M A, SWANSON B J. Mucins in cancer:Protection and control of the cell surface[J]. Nat Rev Cancer, 2004, 4(1):45-60.
[4] GOLDSCHMIDT M, PEÑA L, RASOTTO R, et al. Classification and grading of canine mammary tumors[J]. Vet Pathol, 2011, 48(1):117-131.
[5] 孟迪, 冯晓燕, 进淑娟, 等.CD44v6、MUC1及VEGF在三阴性乳腺癌组织中的表达及其临床意义[J]. 肿瘤学杂志, 2014, 20(2):91-96.
MENG D, FENG X Y, JIN S J, et al. Expressions of CD44v6, MUC1 and VEGF in triple-negative breast cancer and their significances[J]. Journal of Chinese Oncology, 2014, 20(2):91-96. (in Chinese)
[6] BESMER D M, CURRY J M, ROY L D, et al. Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis[J]. Cancer Res, 2011, 71(13):4432-4442.
[7] TINDER T L, SUBRAMANI D B, BASU G D, et al. MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma[J]. J Immunol, 2008, 181(5):3116-3125.
[8] KUFE D W. Mucins in cancer:Function, prognosis and therapy[J]. Nat Rev Cancer, 2009, 9(12):874-885.
[9] ALTSCHULER Y, KINLOUGH C L, POLAND P A, et al. Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state[J]. Mol Biol Cell, 2000, 11(3):819-831.
[10] MARTÍN A, CORTE M D, ÁLVAREZ A M, et al. Prognostic value of pre-operative serum CA 15.3 levels in breast cancer[J]. Anticancer Res, 2006, 26(5B):3965-3971.
[11] WINTER J M, TANG L H, KLIMSTRA D S, et al. A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers[J]. PLoS One, 2012, 7(7):e40157. |